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The lymphokine, IL-2, is a glycoprotein that mediates a variety ofimmunologic
effects in animal models (1). When administered systemically to mice, IL-2 can
mediate the regression ofsubcutaneous tumors as well as pulmonary and hepatic
metastases from selected tumors (2, 3). The characteristics of tumor cells that
determine sensitivity to IL-2 immunotherapy have not been identified. Recent
data from our laboratory demonstrated that IL-2 is capable ofmediatingregres-
sion of 10-d pulmonary macrometastases from two weakly immunogenic 3-
methylcholanthrene (MCA)'-induced sarcomas, yet has no impact on macrome-
tastases derived from two nonimmunogenic sarcomas (4). An Lyt-2-bearing cell
was implicated as a mediator of the regression of weakly immunogenic tumors.
Analysis ofclonallyderivedmurine lymphocyteshas showna correlation between
Lyt-2 phenotype and class I recognition (5). Tumor cell determinants may be
recognized in an associative reaction with self MHC to generate an immune
response, and a role for MHC antigens in controlling tumor immune responses
is suggested by experiments involving alteration of class I expression on tumor
cells by selection (6, 7) or gene transfection (8-10). Increased class I expression
by transfection of several virally transformed or carcinogen-induced murine
tumors was shown to change metastatic potential (8), tumorigenicity (9), or
immunogenicity (10).
In this paper we demonstrate that class I MHC molecules are present on two
weakly immunogenic tumors that respond to high-dose IL-2 therapy, whereas
tumor macrometastases from two nonimmunogenic tumors that were not re-
sponsive to IL-2 immunotherapy express little or no class I MHC antigen. To
test whether modulation of MHC expression could render tumor cells sensitive
to IL-2 immunotherapy, cell lines were derived from a murine melanoma,
B16BL6, by transfection of the class I gene encoding K° and the class II gene
encoding lak (Tanaka, K., and G.Jay, unpublished data).
The original B16BL6 melanoma expressed little or no class I antigen and was
not susceptible to therapy with IL-2. Class I expression induced sensitivity of
macrometastases to therapy with high-dose IL-2 and sensitivity of micrometas-
tases to high- and low-dose IL-2. Lyt-2-bearing cells were involved in regression
'Abbreviation used in this paper: CM, complete media; LAK, lymphokine-activated killer cell;
MCA, 3-methylcholanthrene; neo', neomycin resistance.
1716
￿
Journal of Experimental Medicine - Volume 166
￿
December 1987
￿
1716-1733WEBER ET AL.
￿
1717
of micro- and macrometastases. High-dose IL-2 could also mediate regression of
class I transfectant micrometastases without involving Lyt-2 cells. Class II expres-
sion did not increase the sensitivity of B16BL6 melanoma to IL-2 therapy.
Materials and Methods
Mice.
￿
Female C57BL/6 (C57) mice and (C3H x C57)F, mice, 12-16 wk old, were
obtained from the SmallAnimal Section, VeterinaryResources Branch, National Institutes
of Health, Bethesda, MD.
Tumor Cells.
￿
MCA-101, -102,405, and -106 are MCA-induced fibrosarcomas of C57
origin. They were maintained in vivo in syngeneic mice by serial subcutaneous transplan-
tation of cryopreserved tumor samples as described previously (11). All tumors used were
in the 3rd to 7th transplantation generation. The P815 mastocytoma, syngeneic to DBA/2
mice, was maintained in vivo as ascites tumor.
Interleukin 2.
￿
Human IL-2 was kindly supplied by the Cetus Corp., Emeryville, CA.
The biological and biochemical activities of IL-2 have been described (12). Purified
material had a specific activity of 3.6 x 106 U/mg. In our proliferation assays, ^-1 U of
Cetus Corp. rIL-2 is equivalent to 2-3 U of Biological Response Modifier Program IL-2
standard. The endotoxin level in the purified preparation was <0.1 ng/106 U IL-2, as
measured by a standard limulus assay.
Preparation of Single Cell Suspensions.
￿
Single cell suspensions from solid tumor and
from spleen were prepared as described previously (13). Single cell suspensions were
prepared from monolayers by brief incubation with trypsin at 37°C, removal of cells by
pipetting, centrifugation, and suspension of the pellet in DME containing 10% FCS for
30 min at 37°C . Cells were centrifuged, washed several times with HBSS, and injected
into mice.
Protocolfor TherapyofPulmonaryMetastases.
￿
1-4.5 x 105 tumor cells were injected as
a single cell suspension in 1 ml of HBSS into the tail veins of mice. After 3 d, microme-
tastases were present and invading pulmonary alveoli. By 10 d after injection, grossly
visible metastases were apparent on the lung surface. At 3 or 10 d after tumor cell
injection, therapy with intraperitoneal IL-2 began. Occasional doses of high-dose IL-2
were withheld from all mice if some appeared lethargic. At 17-18 d after injection, mice
were ear-tagged, randomized, and killed. Lungs were removed by opening the thoracic
cavity. 15% India ink was injected into the trachea and lungs were bleached in Fekete's
solution as previously described (13, 14). White tumor nodules on black lung were counted
without knowledge of the treatment given that mouse. Lungs with too many nodules to
count were assigned a value of 300, the approximate upper limit for reliable counting.
After all data were recorded, codes were broken and data analyzed.
Immunoperoxidase Staining.
￿
6-7,um frozen sections on gelatin-coated slides were used.
The avidin-biotin complex technique was employed using a Vector ABC Kit (Vector
Laboratories, Inc., Burlingame, CA). Sections were incubated overnight at 4°C with the
primary antibody. Affinity-purified goat anti-mouse IgG2A was obtained from Southern
Biotechnology Associates, Inc. (Birmingham, AL). Endogenous peroxidase activity was
quenched in all samples with methanol/peroxide. Counterstaining was done with a 1-min
exposure to Mayer's hematoxylin. Normal C57BL/6 spleen sections served as positive
controls for class I or II staining. Mouse mAb 211, which recognizes human T cells and
lymphokine-activated killer (LAK) cells (Fox, B., and S. A. Rosenberg, manuscript in
preparation), or 16-1-2, which detects class I K', served as irrelevant controls.
In Vivo Depletion of Lymphocytes by mAb.
￿
A hybridoma (2.43), producing a rat IgG2b
mAb directed against the Lyt-2 T cell antigen was obtained from American Type Culture
Collection, Rockville, MD. mAb was harvested as ascites from sublethally irradiated (500
rad) DBA/2 mice and kindly provided by Dr. James Yang, NIH. For in vivo lymphocyte
depletion (15), C57 mice received one intravenous injection of 100 Ul of monoclonal
ascites fluid diluted to 0.5 ml with HBSS, from 6-12 h before the first IL-2 injection.
This procedure has been shown to induce depletion of T cell subpopulations in vivo for
up to 14 d (Yang, J., personal communication). Injection of purified rat IgG (Miles1718 INTERLEUKIN 2 THERAPY OF H-2-TRANSFECTED B16 MELANOMA
Laboratories Inc., Naperville, IL) served as a control. It was mixed as 2 mg/ml in 0.5 ml
HBSS. Hybridoma 2.43 ascites was diluted to 2 mg/ml or less in 0.5 ml HBSS.
Fluorescence-activated Cell Sorter Analysis.
￿
Flow cytometry analysis of lymphocyte or
tumor cell surface phenotypes was carried out by indirect fluorescence using a FACS 440
flow microfluorometer (Becton Dickinson & Co., Mountain View, CA), interfaced with a
PDP 11/24 comruter (Digital Equipment Corp., Maynard, MA). Pelleted single cell
suspensions of 10 cells were incubated for 45 min at 4°C with 10-30 A1 of mAbs diluted
in PBS containing 3 % FCS and 0.1 % NaN3. Boundantibodies were detected by incubation
with an appropriately titered FITC-labeled mouse mAb to rat K light chains (MAR 18.5,
Becton Dickinson & Co.) or a goat FITC-labeled mAb to mouse IgG heavy and light
chains (Boehringer Mannheim Biochemicals, Indianapolis, IN) for 45 min at 4°C. Anti-
Kb mAbs 20-8-4 and 28-8-6, anti lab mAb 34-5-3 and anti-Iak mAb 10.2-16 were giftsof
Dr. David Sachs, National Institutes of Health . Anti-Lyt-2 and anti-L3T4 FITC-labeled
mAbs were obtained from Becton Dickinson & Co.
B16 Clones.
￿
BL6-13, CL8-1, and CL8-2 are cell lines derived from murine melanoma
B16BL6 subdone 8 by calcium phosphate cotransfection with a pRSVneo plasmid con-
taining the selectable marker gene encoding resistance to neomycin (BL6-13) or both the
neomycin resistance plasmid and another pRSV plasmid containing the DNA encoding
Kb, a class I antigen (CL8-1, CL8-2). Line BL22 was derived from B16BL6 Clone 8 by
calcium phosphate cotransfection with pRSVneo and another plasmid containing the
genes encoding the a and ,B chains of la', a class II antigen (Tanaka, K., and G. Jay,
unpublished data). All lines were maintained in continuous culture in DMEM with 10%
FCS and passaged twice weekly. Before each experiment, expression of class I antigen on
the cell surface was verified with indirect immunofluoresence on the FACS 440, using
mAb 28-8-6.
Generation ofLAK Cells.
￿
C57 spleen cells in complete medium (CM) were prepared as
previously described (11). 1 ml of CM containing4 x 106 viable splenocytes was added to
each well of a 24-well culture plate (no. 3524, Costar, Cambridge, MA). 1 ml of CM
containing 2,000 U of IL-2 was added to each well. After 3 d of incubation at 37°C with
5% C02, cells were harvested and tested for lytic activity in a 4-h chromium-release assay
(11, 16).
In Vitro Sensitization to Allogeneic Cells.
￿
Conditions for allogeneic in vitro sensitization
have been described in detail (11). Briefly, 4 x 106 responder C57 splenocytes and 2 x
106 irradiated (3,000 rad) DBA/2 spleen stimulator cells were cultured in 2 ml of CM in
individual wells of a 24-well tissue culture plate (Costar), for 4 d at 37°C with 5% C02.
The cells were harvested and tested for cytotoxic activity against tumor or P815 targets
in a 4-h chromium-release assay as described (I1, 16). EL-4 targets were specificity
controls.
Statistics. Statistical analyses were performed by the Wilcoxon rank sum test (13).
Two-sided p values are presented in all experiments. No mice Were excluded from the
statistical evaluations.
Results
Correlation of MCA Sarcoma Class 1 MHC Expression In Vivo with IL-2 Sensitiv-
ity. Previous work from our laboratory (4) using four murine sarcomas, all
induced by the carcinogen 3-methylcholanthrene, established that high-dose IL-
2 immunotherapy mediated 80-90% reduction of 10-d pulmonary macrometas-
tases of weakly immunogenic tumors MCA-105 and -106 but had no effect on
macrometastases of nonimmunogenic tumors MCA-101 and -102.
Expression in vivo of class I and II MHC molecules by macrometastases from
these four sarcomas was tested by immunoperoxidase staining of frozen sections
of lung from mice 10 d after injection with tumor cells. The results in the first
panel of Table I show that tumors 105 and 106 stain positively for class I MHC
using a murine mAb that identifies Kb. Tumors MCA-101 and -102 show noWEBER ET AL.
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TABLE I
Correlation Between ClassIMHC Expression on Murine Sarcomas and
Susceptibility to IL-2 Therapy
* Mice were injected with 1-3 X 105 tumor cells intravenously. Lungs were
removed from animals killed on day 18 after injection, imbedded in OCT
media, and quick-frozen. 6-lAm sections were stained with an immunoperoxi-
dase technique using a vector ABC kit (Vector Laboratories Inc.). Murine
mAb 28-8-6 was used for Kb, a class I determinant. Murine mAb 34-5-6 is
specific for IA', a classII determinant.
$Fresh tumor digested with hyaluronidase, collagenase, and DNAase was pas-
saged once in DMEM with 10% FCS until a homogeneous monolayer grew;
cells were trypsinized and washed, then analyzed using a FACS II analyzer.
Murine mAb 28-8-6 was used to detect K"; 34-5-6 was used for IA°. The
numbers in parentheses represent percent fluorescence in the control sub-
tracted from the experimental sample.
See reference 4. Thenumber represents percentreductionof 10-d pulmonary
metastases treated with 150,000 U of IL-2 intraperitoneally, three times per
day for4 dversus treatment with no IL-2.
staining when tested with the same mAb. A different mAb that identifies both
Kb and Db fails to bind to tumors 101 and 102 (data not shown). No staining of
any of the four sarcomas is seen when a mAb identifying the class II molecule,
Iab, is used. The staining data suggest that tumors 101 and 102 do not express
class I or II MHC molecules. Similar staining data (not shown) were obtained
using subcutaneous tumors generated by the four MCA sarcomas. Tumor cells
derived from the four sarcomas by enzymatic digestion and one passage in vitro
were analyzed by microfluorometry for the presence of class I or 11 MHC
molecules using the same murine mAbs used for immunoperoxidase staining.
The flow microfluorometry profiles are shown in Fig. 1 . Strongly positive class
I staining is seen for tumors 105 and 106, intermediate staining for 102 and
none for 101 . None of the MCA sarcomas stain with an antibody that identifies
the class 11 molecule lab, whereas normal C57BL/6 splenocytes stain strongly
using the same mAb, 34-5-3, in the same experiment. The anti-class I H-26 mAb
did not bind to H-2k C3H splenocytes, and anti H-2k mAb 16-1-2 did not bind
to the MCA sarcomas. Class I MHC is expressed by 105 and 106, both of which
are weakly immunogenic and susceptible to IL-2 immunotherapy. Little or no
class I expression is seen on MCA tumors 101 and 102, both nonimmunogenic
and resistant to IL-2 immunotherapy . None of the tumors expressed class 11
MHC molecules.
Characterization of B16 Cell Lines Transfected with Class I and H MHC
Genes.
￿
To test whether class I MHC expression could increase sensitivity to IL-
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￿
Flow microfluorometric analysis of sarcoma tumor cells. The control antibody
wasgoat anti-mouse FITC-conjugated 1g; theanti-class I mAb was 28-8-6, which recognizes
k° + D°; the anti-class II mAb was 34-5-3, which recognizes Iab. Cell number was measured
on theordinate,andfluorescence intensitywasmeasured on theabcissain arbitrarylogarithmic
units. A total of 106cells were analyzed in each panel.
2 therapy, we used cell lines derived from a subcloned murine melanoma,
B16BL6, that were transfected with either: (a) a plasmid encoding the selectable
marker for Neomycin resistance, neo'; (b) class I MHC gene encoding Kb and
the neo' plasmid; (c) class II genes Iaa and Iasand the neo' plasmid (Tanaka, K.,
and G. Jay, unpublished data). These cell lines were designated BL6-13, CL8-2,
and BL-22, respectively. A northern blot ofRNA from these cell lines is shown
in Fig. 2. Cytoplasmic polyadenylated RNA from the transfected cell lines and
control cells was fractionated on agarose-formaldehyde gels. A synthetic oligo-
nucleotide probe specific to the Kb gene was used for hybridization in the left
lanes A1-4 of Fig. 2; a strong signal in lanes A3 and A4 at 1.8 kb indicates the
presence of class I mRNA in the cell lines CL8-I and CL8-2, two cell lines
transfected with the neo' plasmid and the Kb class I gene. In lanes A1 and A2,
B16BL6 clone 8 and BL6-13, the parental cell line and the line transfected with
the neo' plasmid, do not express detectable class I mRNA. Right lanes B1-B4
show that B16 clone 8, BL6-13, CL8-1, and CL8-2, express normal amounts of
actin mRNA as a positive control. A northern blot ofcytoplasmic polyadenylated
RNA has been performed (Tanaka, K., and G.Jay, unpublished data), showing
that BL22, a cell line transfected with neo' plasmid and the genes encoding a
and ft chains of Iak, expresses mRNA for both chains.
A microfluorometric flow analysis of the control, class 1, and class II transfec-
tant lines was performed using mAbs recognizing Kb, Iab, and la'. The immu-WEBER ET AL.
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FIGURE 2 . Northern blot of RNA from
cell lines B16BL6 clone 8, BL6-13, CL8-1,
andCL8-2, from left to right in each panel.
Polyadenylated cytoplasmic RNA was ob-
tained from theabove cell lines as described
(30), and fractionated on a 1% agarose gel
in the presence of formaldehyde. TheRNA
was transferred from the gel to a nitrocel-
lulose membrane, and the resulting RNA
blot was hybridized to '4P-labeled DNA
probes for the Kb class I gene (A1-A4) or fl-
actin (BI-B4). Hybridization was at 45°C
in 50% formamide, 5X SSC, 5X Denhardt's
solution . The arrow on the right indicates
the position of the class I transcript at 1 .8
kb.
nofluorescence profiles are shown in Fig . 3 . Control cell line BL6-13 does not
bind antibodies 28-8-6 or 34-5-3, indicating that it expresses no class I or II
MHC molecules at its surface . CL8-2 bindsmAb 28-8-6 but not 34-5-3, indicating
that it expresses class I but not class II MHC molecules . BL22 binds mAb 10 .2-
16 but not 28-8-6, indicating the presence of class II lak but no syngeneic class I
molecules . Immunoperoxidase staining ofpulmonary metastases or subcutaneous
tumors generated by BL6-13 or class I transfectant CL8-2 shows positive staining
by a class I mAb only for CL8-2 (data not shown) . Therefore, the class I
transfectant line CL8-2 transcribes mRNA for Kb and expresses the Kb antigen
molecule at its surface in vitro and in pulmonary or subcutaneous tumor in vivo .
The class II transfectant line BL22 similarly transcribes class II mRNA and
expresses the class II molecule at its surface . In contrast, control line BL6-13
neither transcribesmRNA for, nor expresses class I or II MHC molecules .
LAK and Allogeneic CTL Lysis of Transfected Cell Lines.
￿
Class I transfectant
line CL8-2 and control line BL6-13 were tested for sensitivity to lysis in vitro by
syngeneic LAK cells, and by allogeneic CTL . DBA/2 splenocytes sensitized to
irradiated C57BL6 splenocytes should lyse allogeneicb haplotype class I-express-
ing cells, but not cells bearing either syngeneicd haplotype orno class I molecules .
LAK cells are generated by 3-d incubation ofnormal C57BL6 splenocytes in IL-
2, and show MHC-unrestricted lysis ofmany fresh and cultured tumor cell lines
in vitro (17) . The top panel of Fig. 4 shows that control line BL6-13 and
transfected line CL8-2 are lysed equally by LAK cells in a 4-h chromium-release
assay . However, in the bottom panel, allogeneic CTLs lyse class I transfected
CL8-2 cells, but not control line BL6-13 . Therefore, the class I molecules
expressed on line CL8-2 are functional in an MHC-restricted allogeneic CTL
reaction in vitro . LAK lysis in vitro is not an MHC-restricted phenomenon (17),
and LAK cells lyse CL8-2 and BL6-13 equally well .1722 INTERLEUKIN 2 THERAPY OF H-2-TRANSFECTED B16 MELANOMA
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￿
Flow microfluorometric analysis of transfected B16 tumor cells. BL6-13 is a line
transfected with neo' only. CL8-2 is a line cotransfected with neo' and the gene encoding class
I kb. BL22 is a line cotransfected with neo' and the genes encoding a and S chains of class II
lat. The control antibody was goat anti-mouse Ig FITC; the class I antibody was 28-8-6, a
mAb recognizing K" and Db. The class II antibodies were 34-5-3, an mAb recognizing lab, for
BL6-13 and CL8-2, and 10.2-16, a mAb recognizing la', for BL22. Cell number is measured
on the ordinate, and fluorescence intensity is measured on the abcissa in arbitrary logarithmic
units. A total of 106 cells is analyzed in each panel.
Expression ofMHC Class I Renders B16 Transfectant Micro- and Macrometastases
Sensitive to IL-2 Immunotherapy. Micrometastases were generated by intravenous
injection ofcontrol lineBL6-13 and class I transfectantCL8-2. 3 d after injection,
IL-2 therapy at varying doses began and continued for 5 d. Lung metastases
were counted at day 17. The results of two identical experiments are shown in
Table 11, and one experiment is plotted in Fig. 5. Control BL6-13 micrometas-
tases are sensitive to IL-2 immunotherapy in one of the experiments only at the
highest dose of IL-2, 182 vs. 82 metastases, p < 0.05. In contrast, class I
transfected CL8-2 micrometastases showed statistically significant and consider-
able regression at all IL-2 doses, 283 vs. 15 metastases at the highest IL-2 dose
in Exp. 1, 201 vs. 17 metastases in Exp. 2. Expression ofclass I MHC increased
crometastatic sensitivity to IL-2 at doses from 10,000 to 100,000 U i.p. every 8
h given for 5 d, beginning 3 d after injection of tumor cells.
Pulmonary macrometastases weregenerated byintravenous injection oftumor
cells from parental line B16BL6, control line BL6-13, and class I transfectant
line CL8-2. Table III shows theresultsoftwo experiments in which mice received
IL-2 therapy from day 10 to day 14 after tumor injection, and lung metastases
were counted on day 18. In neither experiment was there a demonstrable impact
of IL-2 therapy on the number of pulmonary macrometastases generated by
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FIGURE 4. LAK or allogeneic CTL lysis of
control clone BL6-13 or class I transfectant
clone CL8-2 . Splenocytes from C57BL6 mice
were incubated in complete medium containing
1,000 U of IL-2 per milliliter for 3 d to gen-
erateLAK cells . Splenocytes fromDBA/2mice
were incubated with irradiated C57BL6 sple-
nocytes in complete medium for 5 d at a 2:1
ratio to generate allogeneic CTL . BL6-13 or
CL8-2 were labeled with "Cr and either LAK
or allogeneic CTL cells were used as effectors
in a 4-h "Cr-release assay. Allogeneic CTLs
lysed control target EL4 but cytotoxic activity
was <2% for syngeneic target P815 (not
shown) .
TABLE II
Expression ofClassIMHCAntigen Renders B16 Transfectant 3-d PulmonaryMetastasis
Sensitive to Low- andHigh-dose IL-2
* 2-4.5 X 105 tumor cells were injected intravenously . IL-2 therapy started day 3 after tumor
injection, every 8 h intraperitoneally for 5 d . Mice were killed on day 17 for lung metastases
counting . Each group contains 6-10 mice.
sk Wilcoxon rank sum test of treated groups compared with groups receiving HBSS alone . tp <
0.05; 1p < 0.005 . All others were not significant .
parental B16BL6 (250 vs . 266 metastases), or control line BL6-13 (166 vs . 150
metastases) in Exp . 1 . Neither cell expresses class I MHC antigens . A statistically
significant regression of 10-d macrometastases generated by class I transfected
line CL8-2 is seen in both experiments at the higher dose of IL-2 (152 vs . 27
metastases in Exp . 1, 126 vs . 71 metastases in Exp . 2) . Macrometastases generated
by a second class I transfected cell line, CL8-1, are also sensitive to high-dose IL-
2 (data not shown) .
Expression of Class II MHC Does Not Increase Sensitivity of B16 Transfectant
Micrometastases to IL-2. Line BL22 is derived from B16BL6 by cotransfection
with neo and the genomic DNA encoding the a and IQ chains of la'. The
100
LAK VS. CL8-2 AND BLB-13
80
80 * CL8-2
* BL813
20
F
U 0
X
Number of metastases (t SEM) after treatment with
Exp . Tumor* the following units of IL-2
0 10,000 30,000 100,000
1 BL613 118(17) 120 (17) 137 (28) 102 (14)
CL8-2 283(16) 1081 (12) 171 (6) 151 (5)
2 BL613 187(13) 180 (20) 162 (17) 82* (12)
CL8-2 201(24) 34$ (13) 44$ (33) 171 (9)1724 INTERLEUKIN 2 THERAPY OF H-2-TRANSFECTED B16 MELANOMA
TABLE III
Expression ofClass IMHC Renders B16 Transfectant 10-d Pulmonary
Metastases Sensitive to High-dose IL-2
FIGURE 5 .
￿
The effect of varying doses of IL-2 on 3-
d CL8-2 or BL6-13 micrometastases. 4.5 X 105 class
I transfected CLS-2 or 2 x l0' control neo' trans-
fected cells were injected intravenously. S d later, IL-
2 therapy began intraperitoneally every 8 h for 5 d .
Animals were killed and lung metastases counted on
day 17 . Each dot represents the number of metastases
in one animal.
* 1-4 .5 x 10 5 tumor cells were injected intravenously . II-2 therapy started day 10 after
tumor injection, every 8 h intraperitoneally for 5 d . Mice were killed on day 18 for
counting of lung metastases . Each group contains 6-10 mice .
$ Wiicoxon rank sum test of treated groups compared with groups receiving HBSS
alone. p < 0.05 . All others were not significant .
transfection of a H-2k haplotype class II gene necessitates the use of F, C3H x
C57 animals for generation o£ pulmonary metastases . 3 d after intravenous
injection of class II transfectant BL22 or control BL6-13 cells, IL-2 therapy
began and continued for 5 d . Lung metastases were counted at day 17 . The
results oftwo identical experiments are shown in Table IV . As a positive control
to ensure that IL-2 could mediate regression of micrometastases in F, animals,
two groups ofmice were injected with class I transfectant CL8-2 and treated in
parallel with BL22 or BL6-13 injected mice . In each of the two experiments,
high-dose IL-2 can mediate impressive regression of CL8-2 micrometastases in
F, mice . Similar to our findings in C57BL6 mice, high-dose IL-2 can mediate a
small but statistically significant regression ofBL6-13 control micrometastases in
F, mice, 210 vs . 74 and 51 vs . 21 in two experiments . Class 11 transfectant
micrometastases show no increased sensitivity to low- or high-doses of IL-2 in
either experiment . No significant regression is seen for BL22 in Exp . 1, 172 vs .
115, and moderate regression in Exp . 2, 109 vs. 57, p < 0 .05 . There is no
increase in micrometastatic regression of BL22 versus BL6-13, but there is
Exp . Tumor*
Number of
0
metastases (f SEM)
the following units
20,000
after treatment with
of IL-2
100,000
1 B16 271(18) 281(18) 284 (14)
BL6-13 166(15) 142(23) 150 (27)
CL8-2 152(19) 83(29) 27* (12)
2 B16 238(10) 239(10) 218 (14)
BL6-13 144(23) 157(17) 144 (21)
CL8-2 126(18) 92(11) 71# (11)WEBER ET AL.
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TABLE IV
Expression ofClass II MHC Does NotRender B16 Transfectant 3-dPulmonary
Metastases More Sensitive to IL-2 Therapy
* 2-4.5 x 105 tumorcellswere injected intravenously. IL-2 therapy startedday 3 after
tumor injection, every 8 h intraperitoneally for 5 d. Mice were killed on day 17 for
lung metastases counting. Each group contains 6-10 mice.
$ Wilcoxon rank sum test of treated groups compared with groups receiving HBSS
alone, two-sided, showingp< 0.05.
between BL6-13 and CL8-2. This result suggests that expression of a class II
MHC gene by B16BL6 melanoma cannot induce micrometastatic sensitivity to
IL-2 in semisyngeneic F, mice.
Lyt-2 Cells Mediate Reduction of CL8-2 Macrometastases by High-dose IL-2.
￿
To
establish whether an Lyt-2 cell was involved in mediating regression of 10-d
pulmonary macrometastases induced by class I transfected line CL8-2, rat anti-
Lyt-2 mAb 2.43 was injected intravenously before the onset of IL-2 immuno-
therapy to deplete the Lyt-2 lymphocyte subset. After 5 d of IL-2 therapy, the
lymphocyte populations were examined to verify Lyt-2 depletion. Fig. 6 shows
microfluorometric analyses of splenocytes 5 d after antibody treatment. There
is >85% depletion of Lyt-2+ cells in mice treated with mAb 2.43 . As a control,
fluorescein-conjugated anti-L3T4 mAb was used to measure the L3T4 lympho-
cyte subset in mice treated with anti-Lyt-2 mAb or rat Ig-treated control mice.
The bottom two panels of Fig. 6 show no change in the L3T4* subset after
treatment with mAb 2 .43. The splenocytes from anti-Lyt-2-treated mice are also
unable to generate an allogeneic CTL response in vitro. Splenocytes from
C57BL6 mice were removed on day 5 after mAb 2.43 or rat Ig injection, on the
last day of IL-2 therapy of CL8-2 macrometastases, and cocultured with irradi-
ated DBA/2 splenocytes for 5 d to generate allogeneic CTLs. The allogeneic
CTLs were used as effectors in a 4-h chromium-release assay with tumor line
P815 as the target. The results are shown in Fig. 7 . Mice treated with mAb 2.43
fail to generate allogeneic CTL lysis of P815, whereas control mice treated with
rat Ig generate good allogeneic CTL killing of P815 in vitro. The results of
these microfluorometric and allogeneic CTL assays of in vivo cell depletion are
similar at 14 d after mAb injection (Yang, J., personal communication).
The results of two identical anti-Lyt-2 depletion experiments on the generation
of CL8-2 macrometastases treated with high-dose IL-2 are shown in Table V.
High-dose IL-2 is capable of mediating significant regression of CL8-2 macro-
metastases in both experiments in rat 19-treated control animals (292 for HBSS
Exp. Tumor*
Number of
0
metastases (t SEM) aftertreatment with the
followingunits of 1L-2
10,000 50,000 100,000
1 BL6-13 210(21) 177(18) 152(15) 73$ (18)
BL22 172(23) 156(20) 164(22) 115 (16)
CL8-2 140(27) - - 2: (1)
2 BL6-13 51(12) 75(20) 26(4) 21$ (9)
BL22 109(12) 83(16) 66(20) 57$ (16)
CL8-2 24(7) - - 2$ (1)1726 INTERLEUKIN 2 THERAPY OF H-2-TRANSFECTED B16 MELANOMA
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FIGURE 6.
￿
Flow microfluorometric analysis of splenocytes from mice treated with anti-Lyt-2
mAb 2.43 (left Panels) or control animals treated with rat Ig (right panels). Antibody was
administered intravenously'5 d before analysis, as 100 AI of crudeascitessuspended in 0.5 m1
HBSS. Spleens were removed and single cell suspensions were generated as described previ-
ously(13). The two left panels show staining profiles of control splenocytes using anti-Lyt-2
and anti-L3T4 FITC antibodies (Becton Dickinson & Co.). In the right panels, the staining
profiles ofanti-Lyt-2-depletedsplenocytes are shown. Cell number is measured on theordinate,
and fluorescence intensityis measured on the abcissain arbitrary logarithmic units. A total of
106 cells is analyzed in each panel.
ALLO CTL VS. P815
FIGURE 7.
￿
Ability of splenocytes from
animals treated with anti-Lyt-2 mAb to
generate allogeneic CTL in vitro. 5 d
after C57BL/6 mice received an intra-
venous injection of either mAb 2.43 or
rat Ig, spleen cells were removed and
cultured with irradiated DBA/2 stimu-
lator cells at a ratio of 2:1 for 4 d in
RPMI 1640 complete medium. TheC57
splenocytes were used as effectors in a4-
h chromium-release assay using "Cr-la-
beled P815 cells grown in ascites as the
allogeneic target. Lysis of control syn-
geneic target EL-4 was <5% for all ef-
fectors(not shown).
vs. 169 for 100 x103 U IL-2, and 53 vs. 28, both significant at p < 0.05). As
seen previously, lower doses of IL-2 do not impact on CL8-2 macrometastases.
The effect of high-dose IL-2 on CL8-2 macrometastases in both experiments is
completely abrogated in animals treated with anti-Lyt-2 mAb 2.43 (232 forWEBER ET AL.
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TABLE V
Lyt-2' CellsMediate Reduction ofCL8-2 10-d PulmonaryMetastases by High-doseIL-2
* 4.5 x 105 tumorcellswere injected intravenously. Antibody was injected intravenously 12 h before
starting IL-2 therapy. HBSS or IL-2 was injected intraperitoneally for 5 d every 8 h starting on
day 10 after tumor injection. Each group contains 6-10 mice.
$Wilcoxon rank sum test oftreated groups compared with groups receivingHBSS alone, two-sided;
P < 0.05.
TABLE VI
Lyt-2' CellsMediate Reduction ofCL8-2 3-d PulmonaryMetastases by Low-dose,
butnotHigh-doseIL-2
* 4.5 x 105 tumor cells were injected intravenously. Antibody was injected intrave-
nously 6 hbefore starting IL-2 therapy. HBSS or IL-2 was injected intraperitoneally
for 5 d every 8 h starting on day 3 after tumor injection. Each group contains 6-10
mice.
$§ Wilcoxon rank sum test of treated groups compared with groups receiving HBSS
alone, two-sided. $ P < 0.05. § P <0.005. All others were notsignificant.
HBSS vs. 247 for 100 kD IL-2, and 61 vs. 55, both not significant). This result
suggests that an Lyt-2-bearing cell is involved in the high-dose IL-2-mediated
regression of CL8-2 10-d pulmonary metastases.
Lyt-2 Cells Mediate Reduction of CL8-2 Micrometastases by Low-dose, Not High-
dose IL-2. To establish whether a Lyt-2-bearing cell mediates regression of 3-d
pulmonary micrometastases generated by class I transfected line CL8-2, rat mAb
2.43 was injected intravenously 3 d after tumor cell administration. IL-2 therapy
was begun 6 h later and continued every 8 h for 5 d. Lymphocyte populations
were examined to verify Lyt-2 depletion as in the prior experiments. Virtually
complete depletion was obtained with data similar to that in Figs . 6 and 7 (data
not shown). The results of two similar anti-Lyt-2 depletion experiments on the
generation of CL8-2 micrometastases treated with varying doses of IL-2 are
shown in Table VI. IL-2 at doses ranging from 1-10 x 10' U i.p. every 8 h for
5 d was capable of mediating significant and substantial regression of CL8-2
micrometastases in rat Ig-treated control animals. The regression is invariably
Exp. Treatment*
Number of metastases (t SEM)
units
after treatment
of IL-2
with the following
0 10,000 30,000 100,000
1 Rat Ig 292(5) 260(13) 248(32) 169$ (25)
Anti-Lyt-2 232(31) 287(22) 246(24) 247 (19)
2 Rat Ig 55(9) 55(17) 65(14) 28$ (5)
Anti-Lyt-2 61(7) 56(14) 77(11) 53 (6)
Exp. Treatment*
Number of
0
metastases (± SEM)
following units
10,000
after treatment
IL-2
30,000
with the
100,000
1 RatIg 81 (21) 16# (10) - 9§ (5)
Anti-Lyt-2 93(12) 77 (23) - 121 (4)
2 RatIg 262(23) 186 (71) 511(20) 15§ (6)
Anti-Lyt-2 268(31) 254 (23) 233 (53) 32§ (6)1728 INTERLEUKIN 2 THERAPY OF H-2-TRANSFECTED B16 MELANOMA
greatest at the highest dose of IL-2 (262 vs. 15, and 81 vs. 9, P < 0.005). In anti-
Lyt-2-treated animals, the effect of low-dose IL-2 (1-3 X 10' U) is abrogated,
whereas IL-2 at 10 X 10' U still mediates significant regression of CL8-2
micrometastases (268 vs. 37, and 93 vs. 12, p < 0.005). A Lyt-2-bearing cell is
involved in low-dose IL-2-mediated regression of CL8-2 micrometastases. In
contrast, high-dose IL-2 can mediate significant tumor elimination independent
ofa Lyt-2-bearing cell. This suggests that CL8-2 micrometastases may be elimi-
nated by at least two mechanisms mediated by IL-2; one involving Lyt-2 cells,
and one that does not.
Discussion
Observations made in our laboratory and others suggest that regression of
tumor in animals treated with IL-2 is mediated via the host immune system. The
effect of IL-2 can be eliminated in animals treated with doses of radiation that
suppress cell-mediated immunity (14). Similarly, lethally irradiated mice recon-
stituted with T cell-depleted bone marrow have complete abrogation ofthe IL-
2 antitumor effect (11). Mule et al. (4) have demonstrated that treatment with
high-dose IL-2 can mediate regression of 3-d pulmonary micrometastases from
weakly immunogenic and nonimmunogenic sarcomas. Lyt-2+, as well as asialo
GM1' cells, were involved in regression of immunogenic tumors, though only
asialo GM1' cells were involved in IL-2-mediated regression ofnonimmunogenic
3-d tumors. 10-d pulmonary macrometastases from immunogenic tumors were
susceptible to therapy with high-dose IL-2, but macrometastases from nonim-
munogenic tumors were not. An Lyt-2-bearing cell was involved in the regression
of macrometastases from these weakly immunogenic sarcomas. L3T4-bearing
cells were not involved in the regression of micro- or macrometastases from
either non- or weakly immunogenic sarcomas treated with IL-2. These data
indicated that Lyt-2+ cells are intermediaries in IL-2 immunotherapy of weakly
immunogenic sarcomas.
Since the presence of Lyt-2, a murine T cell marker, determines both cytolytic
function and class I MHC associated recognition of antigen (5), IL-2 may
stimulate specific cytolytic Tcells to recognize tumor antigens in association with
self MHC. Class I MHC molecules are surface glycoproteins that serve as
recognition structures in the interaction of cytolytic T cells and virus-infected
cells (18), but little isknown about their role in tumorcell recognitionbycytolytic
cells. Murine tumors induced by viral or chemical carcinogens can have atten-
uated surface expression ofclass I antigens(8-10). Similarly, many human tumors
appear to be class I deficient, such as neuroblastomas (19), basal cell carcinomas
(20), small cell lung tumors (21), or choriocarcinomas (22).
Modulation of class I expression on murine tumor cells by gene transfection
has been shown to reverse oncogenesis (9), decrease metastatic capability (8), and
potentiate immunogenicity (7, 10). Oncogenic strains ofadenoviruses and ret-
roviruses have evolved mechanisms to selectively downregulate MHC class I
expression (23, 24). Reduced class I expression may represent a mechanism for
tumor cells to evade destruction by cellular immunity, and may be an integral
feature ofoncogene-mediated cellular transformation (25).
As we have shown, IL-2 mediates regression ofadvanced weakly immunogenicWEBER ET AL.
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sarcomametastases viaa Lyt-2' Tcell, and cannot impact on advanced metastases
from nonimmunogenic sarcomas (4). Since interaction ofLyt-2' cells withtumor
cells seemed necessary for the immunotherapeutic effect of IL-2 on advanced
sarcoma metastases, we hypothesized that decreased sensitivity to IL-2 therapy
would correlate with attenuated expression of class I MHC. Upregulation of
class I should promote T cell-mediated tumor recognition and result in an
increased sensitivity to IL-2 immunotherapy.
In accord with this hypothesis, the experiments presented herein show that
weakly immunogenic tumors MCA-105 and -106 express class I MHC molecules
in vivo and in vitro and are susceptible to therapy with high-dose IL-2; nonim-
munogenic tumors 101 and 102 express little or no class I MHC in vivo or in
vitro and advanced metastases are not sensitive to IL-2 therapy. None of the
four tumors express class II MHC antigens. A murine melanoma that expressed
minimal class I MHC was subcloned and transfected with genes encoding class I
molecule Kb or class II molecule lak (Tanaka, K., and G. Jay, unpublished data).
Expression ofclass I MHC significantly increased the sensitivity ofadvanced 10-
d metastases from the B16 transfectant tumor to IL-2 therapy. A more impressive
increase in IL-2 susceptibility was seen when treating 3-d pulmonary microme-
tastases. Lower doses ofIL-2, which did not cause regression ofB16 transfectant
10-d macrometastases, strongly impacted on micrometastases.
Using in vivo antibody depletion to eliminate Lyt-2-bearing cells from treated
mice, we have shown that high-dose IL-2-mediated regression of B16 transfec-
tant macrometastatic tumor involves an Lyt-2' cell, possibly a tumor-specific
cytolytic T cell. Two cell types appear to be involved in the regression of B16
transfectant 3-d micrometastases. At low doses of IL-2 the predominant cell
appears to be Lyt-2'. However, at higher doses ofIL-2, regression of microme-
tastases can also be mediated by Lyt-2- cells, presumably LAK cells. These
findings are in accordance with the work of Mule et al. (4), in which weakly
immunogenic sarcoma macrometastases, shown in this paper to express class I
MHC were susceptible to IL-2 therapy, whereas nonimmunogenic sarcoma
macrometastases shown herein to be devoid ofclass I MHC, were not susceptible
to IL-2 therapy.
We thus postulate a model for IL-2-mediated antitumor effects in which Lyt-
2' cells and LAK cells both play a role in regression of 3-d micrometastases,
whereas only Lyt-2' cells are involved in elimination ofestablished 10-d macro-
metastases. The expression of a single Kb gene was sufficient to render a tumor
sensitive to IL-2 immunotherapy. Class I MHC expression may be necessary for
Lyt-2' cells to mediate the effects of high-dose IL-2 on established tumor since
IL-2 immunotherapy had no impact on non-class I expressing macrometastases
in the paper by Mule et al. (4) or in our experiments. Regression ofadvanced
tumor occurred only at the highest dose of IL-2 that was shown by Mule et al.
(4) to induce endogenous LAK activity in lung and splenic lymphocytes. How-
ever, antibody depletion experiments with Lyt-2 antibody established the neces-
sary involvement of Lyt-2' cells in regression of macrometastases. These data
suggest that tumor-specific cytolytic Tcells may be the effectors ofmacrometas-
tatic regression, and that tumor class I MHC antigens may be important for in
vivo CTL recognition.1730 INTERLEUKIN 2 THERAPY OF H-2-TRANSFECTED B16 MELANOMA
IL-2 mediates regression of 3-d micrometastases in a dose-dependent manner.
At high doses of IL-2, both Lyt-2' cells and endogenous LAK cells are involved
in elimination of tumor in studies by Mule et al. (4). This antitumor effect was
independent of the presence ofclass I MHC. Our work suggests that Lyt-2' cells
are not necessary for regression of B16 transfectant micrometastases at high
doses of IL-2 and tumor regression occurs in the presence or absence ofclass I
MHC. At lower doses of IL-2, Lyt-2' cells appear to be the major effectors of
antitumor activity, and they do not impact on B16 micrometastases devoid of
class I MHC. We conclude that IL-2 mediates its antitumor effect on 3-d
micrometastases by at least two different mechanisms. Low-dose IL-2 stimulates
antitumor activity of Lyt-2' cells against class I-expressing micrometastases.
Higher doses of IL-2 stimulate a broader population of effectors to show MHC-
unrestricted antitumor activity, including Lyt-2' and LAK cells. LAK cells are
the predominant intermediary in regression ofclass I-negative micrometastases,
whereas Lyt-2' cells are more important in elimination ofclass I-expressing 3-d
tumor.
The effects of IL-2 on advanced murine macrometastases are analogous with
the immunotherapy of advanced cancer in humans. High-dose IL-2 alone or
with the concurrent administration of LAK cells has been shown to be capable
of causing significant objective tumor responses and a modest number of com-
plete responses in a variety ofhuman malignancies (26). Many tumors, however,
remain resistant to IL-2 immunotherapy. Since advanced murine tumors that
express class I MHC are more sensitive to IL-2 therapy, the patients whose
tumors show no objective response to IL-2 may be deficient in class I expression
at one or more of the HLA-A, -B, or -C loci. Ample evidence exists for
downregulation of HLA class I loci in human tumors (22-24). We plan to assay
levels of HLA-A, -B, or -C expression in tumors before IL-2 therapy to ask
whether the level of class I expression predicts a response to IL-2. If this is true
then patient tumor cell MHC modulation in vitro can be attempted using IFN-a
or -y or TNF-a, molecules known for their ability to upregulate HLA expression
in human cells (27-29). Lymphocytes sensitized in vitro to tumor-expressing
class I MHC may show increased antitumor activity after adoptive transfer.
Summary
We have shown that two weakly immunogenic MCA sarcomas developed in
our laboratory that are sensitive to high-dose IL-2 immunotherapy express class
I MHC in vivo and in vitro. Two nonimmunogenic MCA sarcomas are relatively
insensitive to IL-2 therapy and express minimal or no class I MHC molecules in
vivo and in vitro. To study the role of MHC in the therapy oftumors with IL-2,
a class I-deficient murine melanoma, B16BL6, was transfected with the Kb class
I gene. Expression of class I MHC rendered B16BL6 advanced pulmonary
macrometastases sensitive to IL-2 immunotherapy. 3-d micrometastases of CL8-
2, a class I transfected clone of B16BL6, were significantly more sensitive to IL-
2 therapy than a control nontransfected line. Expression of la', a class II MHC
molecule, had no effect on IL-2 therapy oftransfectant pulmonary micrometas-
tases in F, mice. By using lymphocyte subset depletion with mAbs directed
against Lyt-2, therapy ofclass I transfectant macrometastases with high-dose IL-WEBER ET AL.
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2 was shown to involve an Lyt-2 cell. In contrast, regression of micrometastases
treated with low-dose IL-2 involved Lyt-2' cells, but regression mediated by
high doses of IL-2 did not. We hypothesize that both LAK and Lyt-2' T cells
effect 1L-2-mediated elimination of micrometastases, but only Lyt-2' T cells are
involved in macrometastatic regression. Low doses of IL-2 stimulate Lyt-2+ cells
to eliminate class I-expressing micrometastases, but high doses of IL-2 can
recruit LAK cells to mediate regression of micrometastases independent of class
I expression. Only high-dose IL-2, mediating its effect predominantly via Lyt-2'
cells, is capable of impacting on MHC class I-expressing macrometastases.
Macrometastases devoid of class 1 MHC antigens appear to be resistant to IL-2
therapy.
We thankJ. J. Mule for helpful discussions and critical review of the manuscript.
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